Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b,Condition 2a,Condition 2b,Condition 3a,Condition 3b,Condition 4,Condition 5,Condition 6 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,16,,CMO:0000727,logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-8.5268,,0.0891,0.3565,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),54608,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,14,,CMO:0000727,logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-8.6139,,0.0646,0.2418,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),54613,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,14,,CMO:0000727,logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-8.4774,,0.0485,0.1815,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56018,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,15,,CMO:0000727,logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-8.5694,,0.0616,0.2387,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56023,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,16,,CMO:0000728,maximum contractile force per wet weight of aorta,,,,1.4669,g/mg,0.0834,0.3335,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours),55764,potassium ion (80 mmol/l) (for 0.2 hours),phenylephrine (10 umol/l) (for 0.2 hours),,,,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,14,,CMO:0000728,maximum contractile force per wet weight of aorta,,,,1.5893,g/mg,0.0997,0.3731,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours),55772,potassium ion (80 mmol/l) (for 0.2 hours),phenylephrine (10 umol/l) (for 0.2 hours),,,,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,15,,CMO:0000728,maximum contractile force per wet weight of aorta,,,,1.2573,g/mg,0.0578,0.2238,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours),57310,controlled sodium content diet (4 %) (for 21 days),,potassium ion (80 mmol/l) (for 0.2 hours),phenylephrine (10 umol/l) (for 0.2 hours),,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,15,,CMO:0000728,maximum contractile force per wet weight of aorta,,,,1.572,g/mg,0.0723,0.28,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours),57318,controlled sodium content diet (4 %) (for 21 days),,potassium ion (80 mmol/l) (for 0.2 hours),phenylephrine (10 umol/l) (for 0.2 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,14,,CMO:0000724,concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,1.5265,E-7mole,0.2983,1.116,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),55870,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,14,,CMO:0000724,concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,1.5511,E-7mole,0.3222,1.2054,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),55878,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,12,,CMO:0000724,concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,0.877,E-7mole,0.1803,0.6244,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),56496,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,11,,CMO:0000724,concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,0.9096,E-7mole,0.1865,0.6184,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),56504,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,16,,CMO:0000722,logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50),,EC50 value is moles/liter,,-7.4606,,0.0325,0.13,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),55251,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,13,,CMO:0000722,logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50),,EC50 value is moles/liter,,-7.215,,0.0929,0.335,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),55259,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,15,,CMO:0000722,logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50),,EC50 value is moles/liter,,-7.3617,,0.1107,0.4288,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56081,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,15,,CMO:0000722,logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50),,EC50 value is moles/liter,,-7.2672,,0.0977,0.3784,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56089,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,12,,CMO:0000731,acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,45.8333,%,4.0524,14.0378,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),54756,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,11,,CMO:0000731,acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,52.0909,%,4.3137,14.307,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),54764,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,14,,CMO:0000731,acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,43.2143,%,3.1399,11.7485,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),57200,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,14,,CMO:0000731,acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,48.6429,%,4.9996,18.7067,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),57208,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,14,,CMO:0000725,logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-6.9746,,0.1176,0.4401,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),55609,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,14,,CMO:0000725,logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-6.9401,,0.0983,0.3677,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),55601,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,12,,CMO:0000725,logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-7.1494,,0.0838,0.2901,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),56891,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,11,,CMO:0000725,logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-7.1525,,0.1029,0.3414,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),56899,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,13,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,31.9231,%,3.3845,12.2029,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),55045,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),,controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,10,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,44.8,%,4.0819,12.9082,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),55049,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),,controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,14,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,35.0714,%,3.425,12.815,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),55073,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,13,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,40.2308,%,4.6009,16.5889,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),55078,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,13,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,32.3077,%,4.0642,14.6537,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),55133,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,10,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,42.4,%,5.1103,16.1603,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),55137,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,14,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,34,%,3.9766,14.879,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),56273,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours), 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,13,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,39.6154,%,4.8457,17.4716,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),56278,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours), 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,12,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,37.4167,%,4.6815,16.217,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours),57136,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,10,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,35.3,%,5.41,17.1078,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours),57141,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,13,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,38.6154,%,2.5383,9.1519,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours),57168,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),,controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours), 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,9,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,44.6667,%,2.5441,7.6322,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours),57172,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),,controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours), 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,14,,CMO:0000732,sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,99.6429,%,0.3571,1.3363,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56305,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,15,,CMO:0000732,sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,98.6667,%,1.1979,4.6394,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56310,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,16,,CMO:0000732,sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,99.4375,%,0.4375,1.75,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56464,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,14,,CMO:0000732,sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,99.5714,%,0.3095,1.1579,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56469,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,16,,CMO:0000726,concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,0.0383,10E-7mol/l,0.0062,0.0247,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),55734,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,14,,CMO:0000726,concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,0.028,10E-7mol/l,0.0041,0.0152,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),55739,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,14,,CMO:0000726,concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,0.036,10E-7mol/l,0.0038,0.0144,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56230,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,15,,CMO:0000726,concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,0.0314,10E-7mol/l,0.0052,0.0201,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56235,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,16,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0362,umol/l,0.0029,0.0115,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54650,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,13,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0821,umol/l,0.0206,0.0742,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54658,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,15,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.064,umol/l,0.0138,0.0533,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54882,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,15,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0749,umol/l,0.0152,0.0589,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54890,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,,